Smart sensors aim to outsmart sepsis in ICU patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years or older. * Patients admitted to the intensive care unit who are at risk of developing sepsis. * Patients with one or more relevant risk factors for sepsis, including pre-existing medical conditions, invasive medical devices, recent procedures or conditions, active infections, clinical risk factors, or prolonged ICU/hospital stay. * Signed informed consent.Exclusion Criteria: * Inability or unwillingness to provide informed consent or comply with study requirements. * ICU stay shorter than 6 hours. * Damaged tattoos, bare skin, recent scar tissue, inflammation, infection, skin barrier alteration, serous or bloody discharge, or metal plates/nails at the area where the Macroduct Advanced system and IDRO device will be placed. * Patients admitted to the ICU with already diagnosed sepsis. * Patients participating in other clinical studies. * Moribund patients or patients with very short life expectancy. * Patients with do-not-resuscitate status at admission. * Patients with implanted devices such as an implanted defibrillator, implanted neurostimulator, implanted pacemaker, or implanted ECG monitor. * Patients in whom short-term interference between the Macroduct device and clinical monitoring cannot be accepted. * Patients with a history of epilepsy or seizures. * Pregnant patients or patients who may be pregnant. * Patients with previous adverse reactions to electrotherapy. * Patients who present adverse reactions during the first sampling with the Macroduct device. * Patients for whom the procedure is contraindicated for medical reasons according to the physician's decision. * Patients with known sensitivity or allergy to pilocarpine nitrate, or any medical contraindication to pilocarpine administration. * Patients in environments with flammable anesthetics or oxygen-enriched environments.